Abstract Details Title First Full Analysis of the ESSENCE Data Set Presents a Cross Section of the SPMS Patient Management in Germany Topic Multiple Sclerosis Presentation(s) P5 - Poster Session 5 (8:00 AM-9:00 AM) Poster/Presentation Number 9-002 Objective ESSENCE (sEcondary progreSsive multiple SclErosis laNdsCape in gErmany) aims at characterizing the health care landscape for patients with Secondary Progressive Multiple Sclerosis (SPMS) across Germany at different types of neurological sites. It is designed to describe the status quo of medical care for patients diagnosed with and at risk for SPMS. Background To date there is no unified understanding across Germany on the definition of SPMS and on how SPMS patients and patients transitioning from RRMS to SPMS should be treated. Thus, it is imperative to assess the current state-of-the-art in SPMS management qualitatively and quantitatively in order to identify common practices and needs. Design/Methods ESSENCE collected data from 100 neurologists with experience in the management of SPMS at selected rehabilitation centers, clinics and office based practices. An online questionnaire was followed by a face-to-face interview. Key aspects cover the diagnosis, current treatment options and disease monitoring. Results An interim analysis (24 of 100 sites) shows that 60% of all diagnosed MS patients are coded as RRMS of which 25% are patients with suspected SPMS. 20% of all MS patients are diagnosed with SPMS of which 30% are currently free of relapse activity or disease progression. Whilst 90% of all RRMS patients are treated with a disease modifying therapy (DMT), 50% of all SPMS patients do not receive a DMT, predominantly due to lack of treatment options. By April 2020 we will present comprehensive data comparing the management of SPMS across rehab, clinical and office based practices including a cross-section of current standards in the diagnosis and management of SPMS patients. Conclusions ESSENCE provides first structured insights into the current SPMS patient management across different neurological sites in Germany. It reveals unmet needs in current SPMS patient care and highlights a strong need for new treatment Options. Authors/Disclosures PRESENTER No disclosure on file Markus W. Heibel, MD (Schering) No disclosure on file